Non-Small Cell Lung Cancer (NSCLC) | Norton Healthcare

Indication: Non-Small Cell Lung Cancer (NSCLC)

An open-label Phase I dose finding trial with BI 891065 alone and in combination with BI 754091 to characterise safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy in patients with advanced and/or metastatic malignancies

Advanced and/or metastatic

Drug Study

Principal Investigator: John Hamm, M.D.
Norton Cancer Institute

Sponsor: Boehringer Ingelheim

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.